Previous 10 | Next 10 |
home / stock / avcn:cc / avcn:cc news
This export marks Avicanna’s 19 th new international market for Avicanna and the 16 th for Aureus branded products. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Jan. 17, 2023 (GLOBE NEWSW...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ”...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ”...
TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based p...
Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC beverage infuser under the Viola brand available in Ontario through the Onta...
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, November 14, 2022 (GLOBE N...
TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that...
TORONTO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-b...
The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain management, neurology, and dermatology, the portal is designed to address potential gap...
Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical ca...
News, Short Squeeze, Breakout and More Instantly...
This marks the first export into Asia, the 18 th international market for Aureus branded products and 21 st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ( “Avicanna” or the “Company” ...
TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based prod...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...